ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
March 15, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
February 08, 2023 12:07 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the...
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
February 06, 2023 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the...
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
December 22, 2022 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 07:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported...
ReShape Lifesciences Announces $750,000 Registered Direct Offering
November 08, 2022 09:28 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
November 07, 2022 13:22 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that...
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
November 03, 2022 08:30 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the...
ReShape Lifesciences to Present at the Q4 Investor Summit
November 02, 2022 09:11 ET
|
ReShape Lifesciences Inc
SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul...
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
October 31, 2022 08:30 ET
|
ReShape Lifesciences Inc
Lap-Band® is the Only FDA Approved Device Indicated for Weight Reduction in Patients With a Body Mass Index (BMI) of at Least 40 kg/m2 or a BMI of at least 30 kg/m2 With One or More Obesity-Related...